Jun. 1 at 5:15 PM
$NVCR just saw RVMD ceo on CNBC. very clear that he will be asking FDA to approve dara for 1L and 2L meta panc, even though most recent results only for 2L. Not sure what FDA will do here. But sure sounds like after ASCO that docs want to be using dara in 1L regardless.
If RVMD is approved in 1L without a ph3 controlled trial, would become impossible / unethical to complete a controlled trial. (no patient would want to be on control arm). On the other hand, a trial comparing Dara vs (TTF + Dara) might actually enroll pretty quickly. I would expect a doc like Picozzi would love to run that trial. That said, RVMD would have to care enough to cooperate, and that is TBD. RVMD ceo talked in interview about many other indications (colon cancer, etc.) that sound like priorities after panc
